Cancer Killers
- Nov 18, 2025
- 2 min read
The Cancer Killers: A story where the stakes are life and death is a documentary about two Australian doctors/researchers who invented a new way to treat cancer. Their approach attacks cancerous cells only, not normal ones. This is novel and, in principle, may apply to many types of cancers. In early trials, some near-death patients had total remission. They started a company many years ago, and after a torturous 20+ years, their treatments have yet to reach the market. The company could have folded many times during its existence. But it may succeed eventually.
I write this to explain the difficulties of investing in life science. It takes a long time, much funding, and great effort. Even with all these, it still might fail. This documentary is educational for research, investment, or treatment. Around 2003, according to a news report, Larry Ellison argued that innovation in computer science had reached a plateau and the future investing belonged to biotech. Decades passed, and Ellison’s prophecy proved too optimistic. This is understandable from my earlier write-ups [1-4].
Most recent advances in AI (LLM) and quantum computing offer a new approach different from conventional digital computing. If you understand AI principles, true artificial intelligence might be still far from reality. But LLM can improve productivity significantly in office work, sales, customer relations, etc.
A few weeks ago, I sent a link to Mark Zuckerberg & Priscilla Chan: How AI Will Cure All Disease (11-7). It also is a completely new approach.
In summary, the above can be groundbreaking biotech research results. However, biotech research has many pitfalls. If you want high returns, computer science and IT are still better. Life sciences are much more complex. Even if you want to invest in biotech, you still can buy QQQ which includes many biotech companies. There are also special indices (ETFs) for biotech which one may consider. I invest a small amount in some biotech stocks because I know the risk vs. reward.
References:
Comments